{"id":51438,"date":"2025-12-18T22:35:32","date_gmt":"2025-12-18T14:35:32","guid":{"rendered":"https:\/\/flcube.com\/?p=51438"},"modified":"2025-12-18T22:35:34","modified_gmt":"2025-12-18T14:35:34","slug":"innocares-soficitinib-wins-nmpa-approval-for-phase-2-3-tyk2-urticaria-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51438","title":{"rendered":"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\/3 TYK2 Urticaria Study"},"content":{"rendered":"\n<p><strong>InnoCare Pharma Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688428:SHA\">SHA: 688428<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a>) announced that China\u2019s National Medical Products Administration (NMPA) approved the Phase 2\/3 clinical trial of <strong>soficitinib (ICP\u2011332)<\/strong>, a novel oral TYK2 inhibitor, for the treatment of <strong>chronic spontaneous urticaria (CSU)<\/strong>. The drug is designed to block cytokine signaling pathways driven by IL\u20114, IL\u201113, and IL\u201131, which promote mast cell activation and inflammatory responses.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Approval Date<\/strong><\/td><td>18\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Soficitinib (ICP\u2011332)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic spontaneous urticaria (CSU)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Highly selective oral TYK2 inhibitor<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First TYK2 inhibitor globally targeting CSU mast cell pathways<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase 2\/3 trial initiation approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Blocks IL\u20114, IL\u201113, and IL\u201131 cytokine signaling pathways that promote mast cell activation and inflammatory responses<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Novel TYK2 inhibitor independent of JAK1\/2\/3; highly selective for TYK2 with minimal off\u2011target effects<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral, once\u2011daily dosing for T\u2011cell\u2011related autoimmune diseases<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> Also being developed for atopic dermatitis, vitiligo, prurigo nodularis, and other urticaria subtypes<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-amp-dose-response\">Clinical Evidence &amp; Dose\u2011Response<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase 2b Design:<\/strong> 187 patients randomized 1:1:1 to soficitinib 75\u202fmg QD, 50\u202fmg QD, or placebo<\/li>\n\n\n\n<li><strong>Primary Endpoint:<\/strong> SLE Responder Index\u20114 (SRI\u20114) response rate at Week\u202f48 (for lupus indication) \u2013 extrapolating to CSU<\/li>\n\n\n\n<li><strong>Dose\u2011Response:<\/strong> 75\u202fmg dose showed superior efficacy to 50\u202fmg, indicating dose\u2011dependent improvement<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Good tolerability and safety profile demonstrated in Phase 2 studies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><th>Context<\/th><\/tr><\/thead><tbody><tr><td><strong>CSU Prevalence<\/strong><\/td><td>~0.5\u20111% globally; ~7\u201114\u202fmillion patients in China<\/td><td>High unmet need for targeted therapy<\/td><\/tr><tr><td><strong>Current SOC<\/strong><\/td><td>Antihistamines, omalizumab (anti\u2011IgE)<\/td><td>Limited efficacy in refractory patients<\/td><\/tr><tr><td><strong>TYK2 Inhibitor Market<\/strong><\/td><td>$2\u20113\u202fbillion potential (autoimmune)<\/td><td>Novel mechanism in dermatology\/immunology<\/td><\/tr><tr><td><strong>Peak Sales Forecast<\/strong><\/td><td><strong>\u00a51\u20111.5\u202fbillion<\/strong> (\u2248\u202fUS$140\u2011210\u202fM) by 2032<\/td><td>15\u201120% share of refractory CSU segment<\/td><\/tr><tr><td><strong>Competitive Advantage<\/strong><\/td><td><strong>First TYK2 inhibitor<\/strong> for CSU; oral dosing vs. injectable omalizumab<\/td><td>Addresses convenience and compliance gaps<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For InnoCare:<\/strong> <strong>Phase 2\/3 approval<\/strong> positions soficitinib as <strong>global leader<\/strong> in TYK2 dermatology; validates <strong>Pharma.AI platform<\/strong> for autoimmune drug discovery; potential for <strong>global out\u2011licensing<\/strong> based on China data.<\/li>\n\n\n\n<li><strong>For Patients:<\/strong> <strong>Oral TYK2 inhibitor<\/strong> offers convenient alternative to biologics; blocks multiple cytokine pathways (IL\u20114\/13\/31) addressing <strong>broader inflammatory cascade<\/strong> than single\u2011target agents; expected to reduce itching, wheal formation, and improve quality of life.<\/li>\n\n\n\n<li><strong>For Market:<\/strong> Demonstrates <strong>China\u2019s capability<\/strong> to develop <strong>first\u2011in\u2011class TYK2 therapeutics<\/strong>; expands InnoCare\u2019s <strong>immunology franchise<\/strong> beyond orelabrutinib (BTK) and zurletrectinib (TRK); <strong>Fast Track potential<\/strong> if US IND is filed based on positive Phase 2 data.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding soficitinib\u2019s clinical development timeline, market penetration, and competitive positioning. Actual results may differ due to regulatory feedback, clinical risks, or competitive responses.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51439,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,919,327,920],"class_list":["post-51438","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-9969","tag-innocare-pharma","tag-sha-688428"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\/3 TYK2 Urticaria Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that China\u2019s National Medical Products Administration (NMPA) approved the Phase 2\/3 clinical trial of soficitinib (ICP\u2011332), a novel oral TYK2 inhibitor, for the treatment of chronic spontaneous urticaria (CSU). The drug is designed to block cytokine signaling pathways driven by IL\u20114, IL\u201113, and IL\u201131, which promote mast cell activation and inflammatory responses.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51438\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\/3 TYK2 Urticaria Study\" \/>\n<meta property=\"og:description\" content=\"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that China\u2019s National Medical Products Administration (NMPA) approved the Phase 2\/3 clinical trial of soficitinib (ICP\u2011332), a novel oral TYK2 inhibitor, for the treatment of chronic spontaneous urticaria (CSU). The drug is designed to block cytokine signaling pathways driven by IL\u20114, IL\u201113, and IL\u201131, which promote mast cell activation and inflammatory responses.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51438\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-18T14:35:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-18T14:35:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1806.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51438#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51438\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\\\/3 TYK2 Urticaria Study\",\"datePublished\":\"2025-12-18T14:35:32+00:00\",\"dateModified\":\"2025-12-18T14:35:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51438\"},\"wordCount\":436,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51438#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1806.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 9969\",\"InnoCare Pharma\",\"SHA: 688428\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51438#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51438\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51438\",\"name\":\"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\\\/3 TYK2 Urticaria Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51438#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51438#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1806.webp\",\"datePublished\":\"2025-12-18T14:35:32+00:00\",\"dateModified\":\"2025-12-18T14:35:34+00:00\",\"description\":\"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that China\u2019s National Medical Products Administration (NMPA) approved the Phase 2\\\/3 clinical trial of soficitinib (ICP\u2011332), a novel oral TYK2 inhibitor, for the treatment of chronic spontaneous urticaria (CSU). The drug is designed to block cytokine signaling pathways driven by IL\u20114, IL\u201113, and IL\u201131, which promote mast cell activation and inflammatory responses.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51438#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51438\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51438#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1806.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1806.webp\",\"width\":1080,\"height\":608,\"caption\":\"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\\\/3 TYK2 Urticaria Study\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51438#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\\\/3 TYK2 Urticaria Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\/3 TYK2 Urticaria Study - Insight, China&#039;s Pharmaceutical Industry","description":"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that China\u2019s National Medical Products Administration (NMPA) approved the Phase 2\/3 clinical trial of soficitinib (ICP\u2011332), a novel oral TYK2 inhibitor, for the treatment of chronic spontaneous urticaria (CSU). The drug is designed to block cytokine signaling pathways driven by IL\u20114, IL\u201113, and IL\u201131, which promote mast cell activation and inflammatory responses.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51438","og_locale":"en_US","og_type":"article","og_title":"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\/3 TYK2 Urticaria Study","og_description":"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that China\u2019s National Medical Products Administration (NMPA) approved the Phase 2\/3 clinical trial of soficitinib (ICP\u2011332), a novel oral TYK2 inhibitor, for the treatment of chronic spontaneous urticaria (CSU). The drug is designed to block cytokine signaling pathways driven by IL\u20114, IL\u201113, and IL\u201131, which promote mast cell activation and inflammatory responses.","og_url":"https:\/\/flcube.com\/?p=51438","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-18T14:35:32+00:00","article_modified_time":"2025-12-18T14:35:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1806.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51438#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51438"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\/3 TYK2 Urticaria Study","datePublished":"2025-12-18T14:35:32+00:00","dateModified":"2025-12-18T14:35:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51438"},"wordCount":436,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51438#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1806.webp","keywords":["Clinical trial approval \/ initiation","HKG: 9969","InnoCare Pharma","SHA: 688428"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51438#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51438","url":"https:\/\/flcube.com\/?p=51438","name":"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\/3 TYK2 Urticaria Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51438#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51438#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1806.webp","datePublished":"2025-12-18T14:35:32+00:00","dateModified":"2025-12-18T14:35:34+00:00","description":"InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that China\u2019s National Medical Products Administration (NMPA) approved the Phase 2\/3 clinical trial of soficitinib (ICP\u2011332), a novel oral TYK2 inhibitor, for the treatment of chronic spontaneous urticaria (CSU). The drug is designed to block cytokine signaling pathways driven by IL\u20114, IL\u201113, and IL\u201131, which promote mast cell activation and inflammatory responses.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51438#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51438"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51438#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1806.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1806.webp","width":1080,"height":608,"caption":"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\/3 TYK2 Urticaria Study"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51438#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare\u2019s Soficitinib Wins NMPA Approval for Phase 2\/3 TYK2 Urticaria Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1806.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51438"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51438\/revisions"}],"predecessor-version":[{"id":51440,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51438\/revisions\/51440"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51439"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}